Submit Manuscript  

Article Details


Evaluating the Safety and Tolerability of Azilsartan Medoxomil Alone or in Combination With Chlorthalidone in the Management of Hypertension: A Systematic Review

Author(s):

Vasiliki Katsi, Christos Michalakeas, Stergios Soulaidopoulos*, Alexios S. Antonopoulos, Charalambos Vlachopoulos, Dimitris Tousoulis and Konstantinos Tsioufis   Pages 1 - 11 ( 11 )

Abstract:


Background and aim: Azilsartan medoxomil (AZM) is the newest representative in the class of angiotensin receptor blockers. Azilsartan medoxomil in combination with the older diuretic chlorthalidone (CLD) in fixed-doses of AZM/CLD 40/12.5 mg and 40/25 mg has been approved by the FDA for use in patients with essential hypertension. We sought to evaluate the safety and tolerability of AZL-M alone and in combination with CLD.

Methods: We conducted a search of pubmed using the keywords ‘azilsartan’, ‘azilsartan medoxomil’, ‘chlorthalidone, ‘safety’, ‘tolerability’ in order to find scientific studies evaluating the safety of these drugs. We included studies report ing side effects of these drugs, alone or in combination, in comparison to placebo or other antihypertensive medications. For our systematic review we followed the PRISMA guidelines.

Results: Azilsartan medoxomil is a potent antihypertensive medicine with an acceptable safety profile. Most commonly reported adverse events are dizziness, headache, fatigue, upper respiratory tract infection and urinary tract infection. Chlorthalidone is more potent and has a considerably longer duration of action than the most commonly prescribed diuretic hydrochlorothiazide. Safety and tolerability between these two drugs is similar with the exception of higher serum uric acid and lower potassium levels with chlorthalidone.

Conclusions: The combination of azilsartan medoxomil with chlorthalidone has been shown to be effective in lowering blood pressure with an acceptable safety and tolerability profile. This fixed-dose combination is an attractive treatment option for hypertension management.

Keywords:

Azilsartan medoxomil, chlorthalidone, safety, tolerability, hypertension.

Affiliation:

First Cardiology Department, Hippokration Hospital, Athens Medical School, National and Kapodistrian University of Athens, Second Cardiology Department, Attikon Hospital, Athens Medical School, National and Kapodistrian University of Athens, Athens, First Cardiology Department, Hippokration Hospital, Athens Medical School, National and Kapodistrian University of Athens, First Cardiology Department, Hippokration Hospital, Athens Medical School, National and Kapodistrian University of Athens, First Cardiology Department, Hippokration Hospital, Athens Medical School, National and Kapodistrian University of Athens, First Cardiology Department, Hippokration Hospital, Athens Medical School, National and Kapodistrian University of Athens, First Cardiology Department, Hippokration Hospital, Athens Medical School, National and Kapodistrian University of Athens



Read Full-Text article